Incident prescriptions for common cardiovascular medications: comparison of recent versus pre-2020 medication adherence and discontinuation in three universal health care systems.

Publication date: Feb 05, 2025

Health system disruptions since onset of the COVID-19 pandemic may have adversely impacted adherence to medications for common cardiovascular risk factors. We examined adherence to and discontinuation of incident prescriptions for medications treating hypertension, dyslipidemia, diabetes, and atrial fibrillation in Ontario, Alberta, and Nova Scotia, Canada. We compared the recent period (April 1, 2020 through most recently available follow-up: September 30, 2021 for Ontario; March 31, 2021 for Alberta; and March 31, 2022 for Nova Scotia) to the baseline, pre-pandemic period (April 1, 2014 through March 31, 2019). In each province, people aged ≥66 years with a valid health number and corresponding incident prescription were included. For each medication class, adherence in the recent period, defined as ≥ 0. 80 proportion-of-days-covered (PDC), was compared to the pre-pandemic period using modified Poisson regression with robust error variance, adjusted for patient characteristics. Similarly adjusted Cox proportional hazards models compared hazard of discontinuation over one year of follow-up between the two time periods. In the recent period, PDC ranged from 48. 9% for dyslipidemia medications in Alberta to 82. 2% for anticoagulants in Nova Scotia. Adherence was not different between periods, with the following exceptions: higher adherence in the recent period for antihypertensives (adjusted risk ratios [aRR] 1. 08, 95% CI 1. 06-1. 10) and dyslipidemics (aRR 1. 07, 95% CI 1. 04-1. 09) in Nova Scotia, and for antihyperglycemics (aRR 1. 10, 95% CI 1. 08-1. 14) and anticoagulants (1. 15, 95% CI 1. 12, 1. 18) in Alberta. Adherence was lower in the recent period only for antihypertensives in Alberta (aRR 0. 95, 95% CI 0. 93, 0. 97). One-year rates of discontinuation ranged from 20. 9% for anticoagulants in the Alberta recent period to 56. 7% for antihypertensives in the Ontario baseline period. The adjusted hazard of discontinuation was lower or unchanged in the recent period for all medication classes. Despite significant health system disruptions since 2020, recent adherence to incident cardiovascular prescriptions was similar or better than before and rates of medication discontinuation were lower. However, interventions are still needed to improve existing, suboptimal adherence.

Open Access PDF

Concepts Keywords
Canada Atrial fibrillation
Covid Cardiovascular risk factors
Diabetes Diabetes
Discontinuation Dyslipidemia
Healthcare delivery
Hypertension
Medication adherence
Medication discontinuation

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH cardiovascular risk factors
disease MESH hypertension
disease MESH dyslipidemia
disease MESH atrial fibrillation
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
disease MESH vascular diseases
disease MESH death
disease MESH hyperlipidemia
disease MESH infection
disease MESH chronic conditions
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Coenzyme M
disease IDO history
disease MESH stroke
disease MESH infarction
drug DRUGBANK Tretamine
disease MESH comorbidity
disease MESH lung disease
disease IDO quality
drug DRUGBANK Spinosad
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH seizure disorders
disease MESH hyperglycemia
drug DRUGBANK Pidolic Acid
disease MESH privacy
disease MESH Emergency
disease IDO intervention
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Allergy
disease MESH panic
disease IDO blood
disease MESH heart failure
disease MESH ST Elevation myocardial infarction
disease MESH Seizure
disease MESH obesity

Original Article

(Visited 3 times, 1 visits today)